MS

Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies
Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies
BioSpace
Merck KGaA
evobrutinib
clinical trials
relapsing multiple sclerosis
MS
Flag link:
Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients
Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients
Fierce Biotech
Genentech
Roche
MS
multiple sclerosis
fenebrutinib
clinical trials
Flag link:
Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data
Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data
Fierce Biotech
Merck KGaA
evobrutinib
MS
multiple sclerosis
clinical trials
Flag link:
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Fierce Pharma
Roche
Ocrevus
MS
multiple sclerosis
clinical trials
Flag link:
A Breakthrough in Interferon-based Therapies for Multiple Sclerosis
A Breakthrough in Interferon-based Therapies for Multiple Sclerosis
BioSpace
Heligenics
MS
multiple sclerosis
beta interferon
genomics
Flag link:
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Flag link:
Teva's trial in high-stakes kickbacks case delayed as company pursues rare pretrial appeal
Teva's trial in high-stakes kickbacks case delayed as company pursues rare pretrial appeal
Fierce Pharma
Teva Pharmaceutical
kickbacks
Copaxone
MS
multiple sclerosis
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
TG shares tumble following licensing deal for MS drug
TG shares tumble following licensing deal for MS drug
BioPharma Dive
TG Therapeutics
MS
multiple sclerosis
Briumvi
Flag link:
Phase III trial results bring subcutaneous Ocrevus closer to its potential approval
Phase III trial results bring subcutaneous Ocrevus closer to its potential approval
Clinical Trials Arena
Roche
Ocrevus
clinical trials
MS
multiple sclerosis
Flag link:
Roche eyes alternate mode of administration for Ocrevus in MS
Roche eyes alternate mode of administration for Ocrevus in MS
Clinical Trials Arena
Roche
Ocrevus
clinical trials
MS
multiple sclerosis
Flag link:
Sanofi sees midphase success in multiple sclerosis decades after safety concerns scuttled peers
Sanofi sees midphase success in multiple sclerosis decades after safety concerns scuttled peers
Fierce Biotech
Sanofi
MS
multiple sclerosis
clinical trials
frexalimab
Flag link:
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Clinical Trials Arena
Roche
fenebrutinib
clinical trials
MS
relapsing multiple sclerosis
Flag link:
J&J opens the valve on $50M MS partnership with Pipeline
J&J opens the valve on $50M MS partnership with Pipeline
Fierce Biotech
JNJ
Pipeline Therapeutics
MS
multiple sclerosis
PIPE-307
Flag link:
Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Fierce Biotech
Merck KGaA
multiple sclerosis
MS
Btk inhibitors
liver damage
Flag link:
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
Flag link:
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Biogen
EMA
Europe
MS
multiple sclerosis
Tecfidera
generics
Flag link:
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Roche
Genentech
patents
MS
multiple sclerosis
legal
Tysabri
Flag link:
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Fierce Pharma
Novartis
Mitsubishi Chemical
multiple sclerosis
MS
Supreme Court
legal
patents
Gilenya
Flag link:
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Endpoints
Novartis
Supreme Court
Gilenya
patents
generics
multiple sclerosis
MS
Flag link:

Pages